| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 20% | +2.8% | $35,502,800 | +$30,394,980 | 9,392,275 | +595% | Federated Hermes, Inc. | 22 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 10% | $32,476,142 | 8,591,572 | Vivo Opportunity Fund Holdings, L.P. | 23 Dec 2025 | |||
| Farallon Capital Partners, L.P. | 10% | $17,160,648 | 4,539,854 | Dapice Joshua J. | 22 Dec 2025 |
As of 30 Sep 2025, 22 institutional investors reported holding 1,979,675 shares of Minerva Neurosciences, Inc. - Common Stock, par value $0.0001 per share (NERV). This represents 2.3% of the company’s total 86,001,722 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 42,380 | $170,368 | +$12,325 | $4.02 | 1 |
| 2025 Q3 | 1,979,675 | $4,208,645 | +$81,860 | $2.10 | 22 |
| 2025 Q2 | 1,944,466 | $3,341,879 | -$12,369 | $1.72 | 18 |
| 2025 Q1 | 1,951,817 | $3,310,087 | -$310,831 | $1.70 | 19 |
| 2024 Q4 | 2,085,897 | $4,630,050 | -$81,975 | $2.22 | 21 |
| 2024 Q3 | 2,118,026 | $5,654,665 | +$83,536 | $2.67 | 19 |
| 2024 Q2 | 2,086,302 | $6,654,936 | -$42,908 | $3.19 | 20 |
| 2024 Q1 | 2,099,790 | $5,416,495 | -$2,569,915 | $2.58 | 20 |
| 2023 Q4 | 2,415,482 | $14,854,825 | +$68,371 | $6.15 | 19 |
| 2023 Q3 | 2,403,051 | $16,580,809 | +$303,012 | $6.90 | 19 |
| 2023 Q2 | 2,352,300 | $19,044,605 | +$5,865,507 | $9.14 | 18 |
| 2023 Q1 | 1,680,901 | $2,687,500 | -$78,110 | $1.60 | 14 |
| 2022 Q4 | 1,729,786 | $2,748,707 | -$3,027,635 | $1.59 | 17 |
| 2022 Q3 | 2,028,914 | $18,733,000 | -$1,898,373 | $9.24 | 23 |
| 2022 Q2 | 2,269,165 | $7,508,000 | +$7,508,000 | $3.31 | 20 |